Osilodrostat phosphate (formerly LCI-699; LCI699; Isturisa), the phosphate salt of Osilodrostat, is a potent 11β-hydroxylase inhibitor that has been approved in 2020 for the treatment of Cushing's disease.

纯度：≥98%

CAS：1315449-72-9